|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RALGPS1 |
Gene summary for RALGPS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RALGPS1 | Gene ID | 9649 |
| Gene name | Ral GEF with PH domain and SH3 binding motif 1 | |
| Gene Alias | RALGEF2 | |
| Cytomap | 9q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q5JS13 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9649 | RALGPS1 | CCI_2 | Human | Cervix | CC | 5.10e-18 | 1.22e+00 | 0.5249 |
| 9649 | RALGPS1 | CCI_3 | Human | Cervix | CC | 1.09e-05 | 5.34e-01 | 0.516 |
| 9649 | RALGPS1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.26e-08 | -4.77e-01 | 0.0155 |
| 9649 | RALGPS1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.37e-02 | -4.65e-01 | 0.096 |
| 9649 | RALGPS1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.65e-08 | -3.90e-01 | 0.294 |
| 9649 | RALGPS1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.39e-07 | -4.81e-01 | 0.3005 |
| 9649 | RALGPS1 | A015-C-203 | Human | Colorectum | FAP | 1.03e-27 | -3.37e-01 | -0.1294 |
| 9649 | RALGPS1 | A015-C-204 | Human | Colorectum | FAP | 6.51e-04 | -3.05e-01 | -0.0228 |
| 9649 | RALGPS1 | A014-C-040 | Human | Colorectum | FAP | 3.40e-02 | -1.58e-01 | -0.1184 |
| 9649 | RALGPS1 | A002-C-201 | Human | Colorectum | FAP | 5.42e-10 | -2.41e-01 | 0.0324 |
| 9649 | RALGPS1 | A002-C-203 | Human | Colorectum | FAP | 5.10e-03 | -1.72e-01 | 0.2786 |
| 9649 | RALGPS1 | A001-C-119 | Human | Colorectum | FAP | 7.77e-04 | -2.86e-01 | -0.1557 |
| 9649 | RALGPS1 | A001-C-108 | Human | Colorectum | FAP | 2.97e-17 | -2.98e-01 | -0.0272 |
| 9649 | RALGPS1 | A002-C-205 | Human | Colorectum | FAP | 5.09e-21 | -5.10e-01 | -0.1236 |
| 9649 | RALGPS1 | A015-C-005 | Human | Colorectum | FAP | 2.25e-03 | -2.82e-01 | -0.0336 |
| 9649 | RALGPS1 | A015-C-006 | Human | Colorectum | FAP | 2.16e-11 | -3.44e-01 | -0.0994 |
| 9649 | RALGPS1 | A015-C-106 | Human | Colorectum | FAP | 2.44e-09 | -2.16e-01 | -0.0511 |
| 9649 | RALGPS1 | A002-C-114 | Human | Colorectum | FAP | 5.15e-15 | -2.76e-01 | -0.1561 |
| 9649 | RALGPS1 | A015-C-104 | Human | Colorectum | FAP | 9.33e-27 | -4.66e-01 | -0.1899 |
| 9649 | RALGPS1 | A001-C-014 | Human | Colorectum | FAP | 1.36e-11 | -3.31e-01 | 0.0135 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
| GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
| GO:00465785 | Cervix | CC | regulation of Ras protein signal transduction | 44/2311 | 189/18723 | 2.05e-05 | 3.73e-04 | 44 |
| GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
| GO:0051056 | Colorectum | AD | regulation of small GTPase mediated signal transduction | 94/3918 | 302/18723 | 1.81e-05 | 3.76e-04 | 94 |
| GO:0046578 | Colorectum | AD | regulation of Ras protein signal transduction | 56/3918 | 189/18723 | 2.85e-03 | 2.14e-02 | 56 |
| GO:00072651 | Colorectum | MSS | Ras protein signal transduction | 91/3467 | 337/18723 | 7.20e-05 | 1.21e-03 | 91 |
| GO:00510561 | Colorectum | MSS | regulation of small GTPase mediated signal transduction | 82/3467 | 302/18723 | 1.31e-04 | 1.99e-03 | 82 |
| GO:00510562 | Colorectum | FAP | regulation of small GTPase mediated signal transduction | 78/2622 | 302/18723 | 3.25e-08 | 2.85e-06 | 78 |
| GO:00072652 | Colorectum | FAP | Ras protein signal transduction | 80/2622 | 337/18723 | 9.61e-07 | 4.33e-05 | 80 |
| GO:00465781 | Colorectum | FAP | regulation of Ras protein signal transduction | 47/2622 | 189/18723 | 4.67e-05 | 9.60e-04 | 47 |
| GO:00510563 | Colorectum | CRC | regulation of small GTPase mediated signal transduction | 69/2078 | 302/18723 | 3.34e-09 | 9.08e-07 | 69 |
| GO:00072653 | Colorectum | CRC | Ras protein signal transduction | 70/2078 | 337/18723 | 1.49e-07 | 1.66e-05 | 70 |
| GO:00465782 | Colorectum | CRC | regulation of Ras protein signal transduction | 43/2078 | 189/18723 | 3.26e-06 | 1.47e-04 | 43 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RALGPS1 | SNV | Missense_Mutation | novel | c.217G>C | p.Glu73Gln | p.E73Q | Q5JS13 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| RALGPS1 | SNV | Missense_Mutation | novel | c.964N>A | p.Asp322Asn | p.D322N | Q5JS13 | protein_coding | tolerated(0.35) | possibly_damaging(0.496) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| RALGPS1 | insertion | Frame_Shift_Ins | novel | c.444_445insGTTTCTCTTAGCATAAAACCAGGAACAGAGCAGT | p.Gln149ValfsTer35 | p.Q149Vfs*35 | Q5JS13 | protein_coding | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| RALGPS1 | SNV | Missense_Mutation | rs755182642 | c.71C>T | p.Ser24Leu | p.S24L | Q5JS13 | protein_coding | tolerated(0.06) | benign(0.17) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| RALGPS1 | SNV | Missense_Mutation | c.1628A>C | p.Lys543Thr | p.K543T | Q5JS13 | protein_coding | tolerated(0.17) | possibly_damaging(0.642) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RALGPS1 | SNV | Missense_Mutation | c.262N>T | p.Ala88Ser | p.A88S | Q5JS13 | protein_coding | tolerated(0.22) | benign(0.083) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RALGPS1 | SNV | Missense_Mutation | novel | c.490A>G | p.Asn164Asp | p.N164D | Q5JS13 | protein_coding | deleterious(0) | benign(0.278) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| RALGPS1 | SNV | Missense_Mutation | c.769N>T | p.His257Tyr | p.H257Y | Q5JS13 | protein_coding | deleterious(0.04) | benign(0.212) | TCGA-CM-4750-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD | |
| RALGPS1 | SNV | Missense_Mutation | c.1499N>C | p.Leu500Pro | p.L500P | Q5JS13 | protein_coding | tolerated(0.07) | probably_damaging(0.983) | TCGA-DM-A0XF-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | mayo | CR | |
| RALGPS1 | SNV | Missense_Mutation | novel | c.516N>T | p.Glu172Asp | p.E172D | Q5JS13 | protein_coding | tolerated(0.69) | benign(0.063) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |